Ran BP-2 CRISPR Activation Plasmid (h): sc-401665-ACT
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- Ran BP-2 CRISPR Activation Plasmid (h) is a synergistic activation mediator (SAM) transcription activation system designed to specifically upregulate gene expression
- Ran BP-2 CRISPR Activation Plasmid (h) consists of three plasmids at a 1:1:1 mass ratio: a plasmid encoding the deactivated Cas9 (dCas9) nuclease (D10A and N863A) fused to the transactivation domain VP64, and a blasticidin resistance gene; a plasmid encoding the MS2-p65-HSF1 fusion protein, and a hygromycin resistance gene; a plasmid encoding a target-specific 20 nt guide RNA fused to two MS2 RNA aptamers, and a puromycin resistance gene
- The resulting SAM complex binds to a site-specific region approximately 200-250 nt upstream of the transcriptional start site and provides robust recruitment of transcription factors for highly efficient gene activation
- gRNAs encoded by Ran BP-2 CRISPR Activation Plasmid (h) and Ran BP-2 CRISPR Activation Plasmid (h2) target distinct regulatory regions upstream of the RANBP2 transcriptional start site. One or both designs may be available
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Ran BP-2 CRISPR Activation Plasmid (h) | sc-401665-ACT | 20 µg | $397.00 |
RANBP2 encodes Ran BP-2 (NUP358), a large nucleoporin that forms cytoplasmic filaments of the nuclear pore complex and coordinates Ran GTPase–dependent nucleocytoplasmic transport. Ran BP-2 also functions as a SUMO E3 ligase, regulating SUMOylation of transport factors and mitotic proteins, and contributes to mitotic progression, kinetochore function, and microtubule organization. Through interactions with importins/exportins and RNA-binding/processing machinery, it links nuclear trafficking to gene expression control and proteostasis. Dysregulation of RANBP2-associated transport and SUMOylation pathways has been connected to neuroinflammatory and neurodegenerative phenotypes and to altered proliferation programs in cancer-relevant cellular contexts.
Ran BP-2 CRISPR Activation Plasmid (h) provides a targeted, non-destructive approach to upregulating endogenous RANBP2 expression without altering the underlying DNA sequence.
Ran BP-2 CRISPR Activation Plasmid (h) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the RANBP2 locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.
Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the RANBP2 transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous Ran BP-2 expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native RANBP2 locus and enabling the study of Ran BP-2-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of Ran BP-2 pathway restoration in tumor cells with silenced or reduced RANBP2 expression.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.